Document is current

Article History

Received: 6 September 2020

Accepted: 3 November 2020

First Online: 12 November 2020

Ethics approval and consent to participate

: This study was conducted in accordance with the Declaration of Helsinki, with approval from the ethics committee of Kyoto University Hospital (E1308). Written informed consent was obtained from all the participants.

: Not applicable.

: K.Murat. received a speaking fee and/or consulting fee from Eisai Co., Ltd. and Astellas Pharma Inc. H.I. has received a research grant and/or speaker fee from Bristol-Myers Squibb, Astellas Pharma Inc., Asahi Kasei Pharma Corporation, and Kyocera Medical Co. M.H. received a research grant and/or speaker fee from Mitsubishi Tanabe Pharma Corporation; Bristol-Myers Squibb; Eisai Co., Ltd.; and Eli Lilly and Company. K. Murak. has received speaking fees and/or consulting fees from Eisai Co., Ltd.; Chugai Pharmaceutical Co., Ltd.; Pfizer Inc.; Bristol-Myers Squibb; Mitsubishi Tanabe Pharma Corporation; UCB Japan Co., Ltd.; Daiichi Sankyo Co., Ltd.; and Astellas Pharma Inc. R.W. has received speaker fees from Mitsubishi Tanabe Pharma Corporation; Pfizer Inc.; Sanofi S.A.; AbbVie GK; Asahi Kasei Pharma Corporation; Eisai Co., Ltd.; Eli Lilly and Company; Bristol-Myers Squibb; and Janssen Pharmaceutical K.K. M.T. has received research grants and/or speaker fees from AbbVie GK; Asahi Kasei Pharma Corporation; Astellas Pharma Inc.; Bristol-Myers Squibb; Chugai Pharmaceutical Co., Ltd.; Eisai Co., Ltd.; Eli Lilly and Company; Pfizer Inc.; UCB Japan Co., Ltd.; Janssen Pharmaceutical K.K.; Mitsubishi Tanabe Pharma Corporation; Novartis Pharma K.K.; Taisho Pharma Co., Ltd.; and Takeda Pharmaceutical Company Limited. S.M. has received a research grant and/or speaker fee from Eisai Co., Ltd.; Chugai Pharmaceutical Co., Ltd.; and Ono Pharmaceutical Co. All other authors declare no competing interests.